Changing the course of cancer treatment
We harness the power of the body's immune system to keep tumor cells in check without harming health or quality of life.
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023
Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the...
Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML
Press Release Stockholm, Sweden, December 6, 2023 CADENCE Phase 2 trial will evaluate vididencel in combination with oral azacitidineRandomized controlled trial in 40 patients, with...
Publication of Year-end Report 2022
Publication of Annual Report 2022
Annual General Meeting
Publication of Q1 Report
Publication of Q2 Report
Publication of Q3 Report
Publication of Year-end Report 2023
Keep up to date
Join our mailing list to receive our latest news.